Brad A. Hartl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brad A. Hartl has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Laura Marcu
Department of Biomedical Engineering, University of California, Davis, USA
6 shared publications Henry Hirschberg
Department of Health Physics and Diagnostic Sciences, University of Nevada, Las Vegas, NV 89154; Beckman Laser Institute and Medical Clinic, University of California, Irvine, CA 92612
2 shared publicationsHtet S. W. Ma
Department of Biomedical Engineering, University of California, Davis, CA 95616, USA
2 shared publicationsKatherine S. Hansen
Department of Surgical and Radiological Sciences, University of California Davis School of Veterinary Medicine, Davis, CA 95616, USA
2 shared publicationsLaura Marcu
Department of Biomedical Engineering, University of California, Davis, CA
2 shared publicationsRuben C. Fragoso
Department of Radiation Oncology, University of California Davis School of Medicine, Sacramento, CA 95817, USA
2 shared publications
Latest Publications
- Open Access
- 1 January 2024
- Published by SPIE-Intl Soc Optical Eng in Neurophotonics
- Vol. 11 (01) , 015008-20
Validation of the Openwater wearable optical system: cerebral hemodynamic monitoring during a breath-hold maneuver
Quantification of cerebral blood flow (CBF) at the bedside holds potential to inform and improve care for a wide range of neurologic diseases, perhaps most notably ischemic stroke in which CBF optimization is a pillar of clinical management. Unfortunately, technical limitations of existing methods for CBF quantification severely impede their clinical utility. The gold standard for non-invasive CBF imaging is -positron emission tomography (PET),1,2 but is logistically complicated, expensive, and exposes the patient to ionizing radiation. Advanced MRI and CT based techniques can quantify CBF, but they provide only snapshots of data and are not suitable for serial bedside monitoring.3 – 7 Invasive tissue monitors, such as the Bowman Perfusion Monitor®, provide real-time physiologic data, including CBF,8 but they are too invasive to be practical in most clinical contexts. Thus, development and translation of a non-invasive bedside modality for CBF measurement is needed.- 1 January 2024
- Published by SPIE-Intl Soc Optical Eng in Neurophotonics
- Vol. 11 (01) , 015008-20
Open AccessValidation of the Openwater wearable optical system: cerebral hemodynamic monitoring during a breath-hold maneuver
Quantification of cerebral blood flow (CBF) at the bedside holds potential to inform and improve care for a wide range of neurologic diseases, perhaps most notably ischemic stroke in which CBF optimization is a pillar of clinical management. Unfortunately, technical limitations of existing methods for CBF quantification severely impede their clinical utility. The gold standard for non-invasive CBF imaging is -positron emission tomography (PET),1,2 but is logistically complicated, expensive, and exposes the patient to ionizing radiation. Advanced MRI and CT based techniques can quantify CBF, but they provide only snapshots of data and are not suitable for serial bedside monitoring.3 – 7 Invasive tissue monitors, such as the Bowman Perfusion Monitor®, provide real-time physiologic data, including CBF,8 but they are too invasive to be practical in most clinical contexts. Thus, development and translation of a non-invasive bedside modality for CBF measurement is needed. - 9 August 2019
- Published by Wiley in Journal of Biophotonics
- Vol. 13 (1) , e201900108
Real‐time augmented reality for delineation of surgical margins during neurosurgery using autofluorescence lifetime contrast
Current clinical brain imaging techniques used for surgical planning of tumor resection lack intraoperative and real‐time feedback; hence surgeons ultimately rely on subjective evaluation to identify tumor areas and margins. We report a fluorescence lifetime imaging (FLIm) instrument (excitation: 355 nm; emission spectral bands: 390/40 nm, 470/28 nm, 542/50 nm and 629/53 nm) that integrates with surgical microscopes to provide real‐time intraoperative augmentation of the surgical field of view with fluorescent derived parameters encoding diagnostic information. We show the functionality and safety features of this instrument during neurosurgical procedures in patients undergoing craniotomy for the resection of brain tumors and/or tissue with radiation damage. We demonstrate in three case studies the ability of this instrument to resolve distinct tissue types and pathology including cortex, white matter, tumor and radiation‐induced necrosis. In particular, two patients with effects of radiation‐induced necrosis exhibited longer fluorescence lifetimes and increased optical redox ratio on the necrotic tissue with respect to non‐affected cortex, and an oligodendroglioma resected from a third patient reported shorter fluorescence lifetime and a decrease in optical redox ratio than the surrounding white matter. These results encourage the use of FLIm as a label‐free and non‐invasive intraoperative tool for neurosurgical guidance.
- 9 August 2019
- Published by Wiley in Journal of Biophotonics
- Vol. 13 (1) , e201900108
Real‐time augmented reality for delineation of surgical margins during neurosurgery using autofluorescence lifetime contrast
Current clinical brain imaging techniques used for surgical planning of tumor resection lack intraoperative and real‐time feedback; hence surgeons ultimately rely on subjective evaluation to identify tumor areas and margins. We report a fluorescence lifetime imaging (FLIm) instrument (excitation: 355 nm; emission spectral bands: 390/40 nm, 470/28 nm, 542/50 nm and 629/53 nm) that integrates with surgical microscopes to provide real‐time intraoperative augmentation of the surgical field of view with fluorescent derived parameters encoding diagnostic information. We show the functionality and safety features of this instrument during neurosurgical procedures in patients undergoing craniotomy for the resection of brain tumors and/or tissue with radiation damage. We demonstrate in three case studies the ability of this instrument to resolve distinct tissue types and pathology including cortex, white matter, tumor and radiation‐induced necrosis. In particular, two patients with effects of radiation‐induced necrosis exhibited longer fluorescence lifetimes and increased optical redox ratio on the necrotic tissue with respect to non‐affected cortex, and an oligodendroglioma resected from a third patient reported shorter fluorescence lifetime and a decrease in optical redox ratio than the surrounding white matter. These results encourage the use of FLIm as a label‐free and non‐invasive intraoperative tool for neurosurgical guidance.
- Open Access
- 5 July 2018
- Published by Optica Publishing Group in Biomedical Optics Express
- Vol. 9 (8) , 3559-3580
Label-free fluorescence lifetime spectroscopy detects radiation-induced necrotic changes in live brain in real-time
Current clinical imaging modalities do not reliably identify brain tissue regions with necrosis following radiotherapy. This creates challenges for stereotaxic biopsies and surgical-decision making. Time-resolved fluorescence spectroscopy (TRFS) provides a means to rapidly identify necrotic tissue by its distinct autofluorescence signature resulting from tissue breakdown and altered metabolic profiles in regions with radiation damage. Studies conducted in a live animal model of radiation necrosis demonstrated that necrotic tissue is characterized by respective increases of 27% and 108% in average lifetime and redox ratio, when compared with healthy tissue. Moreover, radiation-damaged tissue not visible by MRI but confirmed by histopathology, was detected by TRFS. Current results demonstrate the ability of TRFS to identify radiation-damaged brain tissue in real-time and indicates its potential to assist with surgical guidance and MRI-guided biopsy procedures.
- 5 July 2018
- Published by Optica Publishing Group in Biomedical Optics Express
- Vol. 9 (8) , 3559-3580
Open AccessLabel-free fluorescence lifetime spectroscopy detects radiation-induced necrotic changes in live brain in real-time
Current clinical imaging modalities do not reliably identify brain tissue regions with necrosis following radiotherapy. This creates challenges for stereotaxic biopsies and surgical-decision making. Time-resolved fluorescence spectroscopy (TRFS) provides a means to rapidly identify necrotic tissue by its distinct autofluorescence signature resulting from tissue breakdown and altered metabolic profiles in regions with radiation damage. Studies conducted in a live animal model of radiation necrosis demonstrated that necrotic tissue is characterized by respective increases of 27% and 108% in average lifetime and redox ratio, when compared with healthy tissue. Moreover, radiation-damaged tissue not visible by MRI but confirmed by histopathology, was detected by TRFS. Current results demonstrate the ability of TRFS to identify radiation-damaged brain tissue in real-time and indicates its potential to assist with surgical guidance and MRI-guided biopsy procedures.
- 13 March 2017
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 93 (7) , 676-682
The effect of radiation dose on the onset and progression of radiation-induced brain necrosis in the rat model
Purpose: To provide a comprehensive understanding of how the selection of radiation dose affects the temporal and spatial progression of radiation-induced necrosis in the rat model. Materials and methods: Necrosis was induced with a single fraction of radiation exposure, at doses ranging between 20 and 60 Gy, to the right hemisphere of 8-week-old Fischer rats from a linear accelerator. The development and progression of necrosis in the rats was monitored and quantified every other week with T1- and T2-weighted gadolinium contrast-enhanced MRI studies. Results: The time to onset of necrosis was found to be dose-dependent, but after the initial onset, the necrosis progression rate and total volume generated was constant across different doses ranging between 30 and 60 Gy. Radiation doses less than 30 Gy did not develop necrosis within 33 weeks after treatment, indicating a dose threshold existing between 20 and 30 Gy. Conclusion: The highest dose used in this study led to the shortest time to onset of radiation-induced necrosis, while producing comparable disease progression dynamics after the onset. Therefore, for the radiation-induced necrosis rat model using a linear accelerator, the most optimum results were generated from a dose of 60 Gy.
- 13 March 2017
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 93 (7) , 676-682
The effect of radiation dose on the onset and progression of radiation-induced brain necrosis in the rat model
Purpose: To provide a comprehensive understanding of how the selection of radiation dose affects the temporal and spatial progression of radiation-induced necrosis in the rat model. Materials and methods: Necrosis was induced with a single fraction of radiation exposure, at doses ranging between 20 and 60 Gy, to the right hemisphere of 8-week-old Fischer rats from a linear accelerator. The development and progression of necrosis in the rats was monitored and quantified every other week with T1- and T2-weighted gadolinium contrast-enhanced MRI studies. Results: The time to onset of necrosis was found to be dose-dependent, but after the initial onset, the necrosis progression rate and total volume generated was constant across different doses ranging between 30 and 60 Gy. Radiation doses less than 30 Gy did not develop necrosis within 33 weeks after treatment, indicating a dose threshold existing between 20 and 30 Gy. Conclusion: The highest dose used in this study led to the shortest time to onset of radiation-induced necrosis, while producing comparable disease progression dynamics after the onset. Therefore, for the radiation-induced necrosis rat model using a linear accelerator, the most optimum results were generated from a dose of 60 Gy.
- 1 January 2016
- Published by Begell House Inc. Publishers in Journal of Environmental Pathology, Toxicology and Oncology
- Vol. 35 (2) , 185-192
Activating Photodynamic Therapy in vitro with Cerenkov Radiation Generated from Yttrium-90
The translation of photodynamic therapy (PDT) to the clinical setting has primarily been limited to easily accessible and/or superficial diseases, for which traditional light delivery can be performed noninvasively. Cerenkov radiation, as generated from medically relevant radionuclides, has been suggested as a means to deliver light to deeper tissues noninvasively to overcome this depth limitation. This article investigates the utility of Cerenkov radiation, as generated from the radionuclide yttrium-90, for activating the PDT process using clinically approved aminolevulinic acid at 1.0 mm and also the more efficient porphyrin-based photosensitizer mesotetraphenylporphine with two sulfonate groups on adjacent phenyl rings (TPPS2a) at 1.2 µm. Experiments were conducted with monolayer cultured glioma and breast tumor cell lines. Although aminolevulinic acid proved to be ineffective for generating a therapeutic effect at all but the highest activity levels, TPPS2a produced at least a 20% therapeutic effect at activities ranging from 6 to 60 µCi/well for the C6 glioma cell line. Importantly, these results demonstrate for the first time, to our knowledge, that Cerenkov radiation generated from a radionuclide can be used to activate PDT using clinically relevant photosensitizers. These results therefore provide evidence that it may be possible to generate a phototherapeutic effect in vivo using Cerenkov radiation and clinically relevant photosensitizers.
- 1 January 2016
- Published by Begell House Inc. Publishers in Journal of Environmental Pathology, Toxicology and Oncology
- Vol. 35 (2) , 185-192
Activating Photodynamic Therapy in vitro with Cerenkov Radiation Generated from Yttrium-90
The translation of photodynamic therapy (PDT) to the clinical setting has primarily been limited to easily accessible and/or superficial diseases, for which traditional light delivery can be performed noninvasively. Cerenkov radiation, as generated from medically relevant radionuclides, has been suggested as a means to deliver light to deeper tissues noninvasively to overcome this depth limitation. This article investigates the utility of Cerenkov radiation, as generated from the radionuclide yttrium-90, for activating the PDT process using clinically approved aminolevulinic acid at 1.0 mm and also the more efficient porphyrin-based photosensitizer mesotetraphenylporphine with two sulfonate groups on adjacent phenyl rings (TPPS2a) at 1.2 µm. Experiments were conducted with monolayer cultured glioma and breast tumor cell lines. Although aminolevulinic acid proved to be ineffective for generating a therapeutic effect at all but the highest activity levels, TPPS2a produced at least a 20% therapeutic effect at activities ranging from 6 to 60 µCi/well for the C6 glioma cell line. Importantly, these results demonstrate for the first time, to our knowledge, that Cerenkov radiation generated from a radionuclide can be used to activate PDT using clinically relevant photosensitizers. These results therefore provide evidence that it may be possible to generate a phototherapeutic effect in vivo using Cerenkov radiation and clinically relevant photosensitizers.
- 21 June 2015
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 407 (27) , 8291-8301
Combined fiber probe for fluorescence lifetime and Raman spectroscopy
In this contribution we present a dual modality fiber optic probe combining fluorescence lifetime imaging (FLIm) and Raman spectroscopy for in vivo endoscopic applications. The presented multi-spectroscopy probe enables efficient excitation and collection of fluorescence lifetime signals for FLIm in the UV/visible wavelength region, as well as of Raman spectra in the near-IR for simultaneous Raman/FLIm imaging. The probe was characterized in terms of its lateral resolution and distance dependency of the Raman and FLIm signals. In addition, the feasibility of the probe for in vivo FLIm and Raman spectral characterization of tissue was demonstrated. An image comparison between FLIm and Raman spectroscopy acquired with the bimodal probe onseveral tissue samples
- 21 June 2015
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 407 (27) , 8291-8301
Combined fiber probe for fluorescence lifetime and Raman spectroscopy
In this contribution we present a dual modality fiber optic probe combining fluorescence lifetime imaging (FLIm) and Raman spectroscopy for in vivo endoscopic applications. The presented multi-spectroscopy probe enables efficient excitation and collection of fluorescence lifetime signals for FLIm in the UV/visible wavelength region, as well as of Raman spectra in the near-IR for simultaneous Raman/FLIm imaging. The probe was characterized in terms of its lateral resolution and distance dependency of the Raman and FLIm signals. In addition, the feasibility of the probe for in vivo FLIm and Raman spectral characterization of tissue was demonstrated. An image comparison between FLIm and Raman spectroscopy acquired with the bimodal probe onseveral tissue samples
- Open Access
- 10 February 2015
- Published by Optica Publishing Group in Biomedical Optics Express
- Vol. 6 (3) , 770-779
Characterizing low fluence thresholds for in vitro photodynamic therapy
The translation of photodynamic therapy (PDT) to the clinic has mostly been limited to superficial diseases where traditional light delivery is noninvasive. To overcome this limitation, a variety of mechanisms have been suggested to noninvasively deliver light to deep tissues. This work explores the minimum amount of light required by these methods to produce a meaningful PDT effect in the in vitro setting under representative low fluence and wavelength conditions. This threshold was found to be around 192 mJ/cm2 using the clinically approved photosensitizer aminolevulinic acid and 12 mJ/cm2 for the more efficient, second generation photosensitizer TPPS2a.
- 10 February 2015
- Published by Optica Publishing Group in Biomedical Optics Express
- Vol. 6 (3) , 770-779
Open AccessCharacterizing low fluence thresholds for in vitro photodynamic therapy
The translation of photodynamic therapy (PDT) to the clinic has mostly been limited to superficial diseases where traditional light delivery is noninvasive. To overcome this limitation, a variety of mechanisms have been suggested to noninvasively deliver light to deep tissues. This work explores the minimum amount of light required by these methods to produce a meaningful PDT effect in the in vitro setting under representative low fluence and wavelength conditions. This threshold was found to be around 192 mJ/cm2 using the clinically approved photosensitizer aminolevulinic acid and 12 mJ/cm2 for the more efficient, second generation photosensitizer TPPS2a.
- 1 January 2013
- Published by Springer Nature
- p. 1949-1952
4D-Video Usefulness For Tracking Respiration Motion in 4DCT Scans and Targeting Small Mobile Tumors
- 1 January 2013
- Published by Springer Nature
- p. 1949-1952
4D-Video Usefulness For Tracking Respiration Motion in 4DCT Scans and Targeting Small Mobile Tumors
- 1 January 2013
- Published by Optica Publishing Group
- p. JT2A.11
Photodynamic Therapy Activated with Cerenkov Luminescence from Beta-Emitting Radionuclides
Cerenkov luminescence generated from radionuclides was used as a novel light source for photodynamic therapy. This technique, in conjunction with administration of δ-aminolevulinic acid, was shown to inhibit growth of U-87 glioblastoma cells in vitro.
- 1 January 2013
- Published by Optica Publishing Group
- p. JT2A.11
Photodynamic Therapy Activated with Cerenkov Luminescence from Beta-Emitting Radionuclides
Cerenkov luminescence generated from radionuclides was used as a novel light source for photodynamic therapy. This technique, in conjunction with administration of δ-aminolevulinic acid, was shown to inhibit growth of U-87 glioblastoma cells in vitro.
- 1 July 2012
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Selected Topics in Quantum Electronics
- Vol. 18 (4) , 1465-1477
Fluorescence Lifetime Spectroscopy and Imaging in Neurosurgery
Clinical outcome of patients diagnosed with primary brain tumor has been correlated with the extent of surgical resection. In treating this disease, the neurosurgeon must balance between an aggressive, radical resection and minimizing the loss of healthy, functionally significant brain tissue. Numerous intraoperative methodologies and technological approaches have been explored as a means to improve the accuracy of surgical resection. This paper presents an overview of current conventional techniques and new emerging technologies with potential to impact the area of image-guided surgery of brain tumors. Emphasis is placed on techniques based on endogenous fluorescence lifetime contrast and their potential for intraoperative diagnosis of brain tumors.
- 1 July 2012
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Selected Topics in Quantum Electronics
- Vol. 18 (4) , 1465-1477
Fluorescence Lifetime Spectroscopy and Imaging in Neurosurgery
Clinical outcome of patients diagnosed with primary brain tumor has been correlated with the extent of surgical resection. In treating this disease, the neurosurgeon must balance between an aggressive, radical resection and minimizing the loss of healthy, functionally significant brain tissue. Numerous intraoperative methodologies and technological approaches have been explored as a means to improve the accuracy of surgical resection. This paper presents an overview of current conventional techniques and new emerging technologies with potential to impact the area of image-guided surgery of brain tumors. Emphasis is placed on techniques based on endogenous fluorescence lifetime contrast and their potential for intraoperative diagnosis of brain tumors.